Highlights
- Third quarter 2026 product revenue, net, was $127.3 million, compared with $97.8 million, and income from operations was $71.1 million.
- Net income was $63.1 million, compared with $79.4 million, and Diluted Earnings per Share were $2.05, compared with $2.66.
- In October 2026, the board authorized the repurchase of up to $400 million of common stock, with no expiration date.
- Management said it now expects several clinical readouts in 2027, including KB801 top-line results and KB407 interim results.
Krystal Biotech, Inc. (NASDAQ:KRYS) shares were trading at USD 314.74 on November 20, 2026, down 0.34%, with a relative Volume at time of 1.91. The commercial-stage gene therapy company filed its Quarterly Report for the period ended September 30, 2026 on November 2, authorized a repurchase program of up to $400 million in October and updated the timing of several clinical readouts on its earnings call.
Krystal Biotech is a Delaware corporation with principal executive offices in Pittsburgh, Pennsylvania. It describes itself as a fully integrated, global, commercial-stage biotechnology company. Its product is VYJUVEK, sold in the United States and internationally, including Germany, France and Japan, and it has a pipeline in rare dermatology, ophthalmology, lung disease and oncology. The company reports net product Revenue as a single line and its fiscal year ends on December 31.
Third Quarter 2026 Results
For the three months ended September 30, 2026, product revenue, net, was $127.3 million, compared with $97.8 million a year earlier. Cost of Goods Sold was $7.6 million, compared with $4.3 million. Research and Development expense was $14.9 million, compared with $14.6 million, and selling, general and administrative expense was $33.7 million, compared with $37.6 million. Income from operations was $71.1 million, compared with $41.4 million.
Income before income taxes was $80.1 million, compared with $48.0 million. Income tax expense was $17.1 million, compared with an income tax benefit of $31.4 million. Net Income was $63.1 million, compared with $79.4 million. Earnings per share were $2.13 basic and $2.05 diluted, compared with $2.74 basic and $2.66 diluted. Comprehensive income was $58.2 million, compared with $79.3 million.
On the call, management said US net revenue was $95.3 million and international revenue was $32 million, and that gross Margin was 94% compared with 96% a year earlier. It said the prior-year quarter included the release of most of the valuation allowance against deferred tax assets.
Nine-Month Results and Balance Sheet
For the nine months ended September 30, 2026, product revenue, net, was $362.9 million, compared with $282.0 million. Income from operations was $183.3 million, compared with $117.0 million. Net income was $173.8 million, compared with $153.4 million, and diluted earnings per share were $5.66, compared with $5.14.
Net cash provided by Operating Activities was $246.4 million, compared with $123.4 million. Cash and cash equivalents were $462.8 million at September 30, 2026, compared with $496.3 million at December 31, 2025. Total Assets were $1.59 billion, compared with $1.33 billion, total liabilities were $150.5 million and total stockholders' Equity was $1.44 billion.
Share Repurchase Program
In October 2026, the Board of Directors authorized the repurchase of up to $400 million of common stock. Shares may be repurchased from time to time through open market purchases, privately negotiated transactions or other means. The program has no expiration date, does not obligate the company to acquire any particular amount of stock and may be modified, suspended or discontinued at any time. Management said it expects to deploy the authorization over the next two years.
Clinical Readout Timing and Outlook
Management acknowledged on the November 2 call that some clinical results will take longer than initially expected. For KB408 in dystrophic epidermolysis bullosa, it expects the last patient, last visit in February 2027, with top-line results shortly thereafter. For KB801 in neurotrophic keratitis, it said enrollment progressed more slowly than anticipated and it now expects to complete enrollment and report top-line results in 2027. For KB407 in cystic fibrosis, it anticipates interim results in the first half of 2027.
Management also said it expects to share a data update for the HHD-01 repeat-dose study before year end. It revised its full year non-GAAP R&D and SG&A guidance to $155 million to $165 million, from prior guidance of $175 million to $195 million.






Please wait processing your request...